Pathogenic LRRK2 compromises the subcellular distribution of lysosomes in a Rab12‐RILPL1 ‐dependent manner
The FASEB Journal · 2023
DOI: 10.1096/fj.202200780rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Kyohei Ito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Lysosomes, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, rab GTP-Binding Proteins, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Biogen, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Mutations in leucine‐rich repeat kinase 2 (LRRK2) cause familial Parkinson's disease (PD). Recent studies have shown that LRRK2 physiologically phosphorylates several Rab family proteins including Rab12 and that this phosphorylation is accelerated by the pathogenic mutations in LRRK2, although the significance in the PD pathogenesis remains unknown. Here we examined the effect of the overexpression of LRRK2 on the distribution of organelles in cultured cells and found that lysosomes become clustered in a perinuclear region upon the overexpression of pathogenic mutant LRRK2 in a manner dependent on its kinase activity. The perinuclear clustering of lysosomes was abolished by knocking out RAB12 as well as its effector protein RILPL1 . Re‐expression of Rab12 in RAB12 knockout cells suggested that the phosphorylation at Ser106 of Rab12 is required for the perinuclear clustering of lysosomes. Moreover, phosphorylated Rab12 was also accumulated on the clustered lysosomes, and the phosphorylation of Rab12 increased its interaction with RILPL1, leading us to conclude that the increase in the phosphorylation of Rab12 by pathogenic LRRK2 compromised intracellular lysosomal transport via the enhanced interaction of Rab12 with RILPL1. These data suggest the involvement of abnormal regulation of lysosomal transport in the LRRK2‐mediated pathogenesis of PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
- HACARUS, Inc., Kyoto, Japan.
- Department of Biomolecular Chemistry, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan.
- Social Cooperation Program of Brain and Neurological Disorders, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Genta Ito, Taisuke Tomita
Förderung
- Biogen
- Japan Society for the Promotion of Science
Zitieren
APA
Ito, K., Araki, M., Katai, Y., Nishimura, Y., Imotani, S., Inoue, H., Ito, G., & Tomita, T. (2023). Pathogenic LRRK2 compromises the subcellular distribution of lysosomes in a Rab12‐RILPL1 ‐dependent manner. The FASEB Journal. https://doi.org/10.1096/fj.202200780rr
Vancouver
Ito K, Araki M, Katai Y, Nishimura Y, Imotani S, Inoue H, et al. Pathogenic LRRK2 compromises the subcellular distribution of lysosomes in a Rab12‐RILPL1 ‐dependent manner. The FASEB Journal. 2023. doi:10.1096/fj.202200780rr
BibTeX
@article{Ito2023,
author = {Ito, Kyohei and Araki, Miho and Katai, Yuta and Nishimura, Yuki and Imotani, Sota and Inoue, Haruki and Ito, Genta and Tomita, Taisuke},
title = {Pathogenic LRRK2 compromises the subcellular distribution of lysosomes in a Rab12‐RILPL1 ‐dependent manner},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202200780rr}
}
EUVIMED